Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

Mauro, Fr; Tedeschi, A; Piciocchi, A; Motta, M; Iannella, E; Farina, L; Scarfo, L; Marasca, R; Coscia, Marta; Cortelezzi, A; Laurenti, L; Melpignano, A; Zinzani, Pl; Molica, S; Re, F; Andriani, A; Vincelli, Di; Visco, C; Gozzetti, A; Orlandi, Em; Trentin, L; Tani, M; Califano, C; Tagariello, G; Ghia, P; Caputo, Md; Salaroli, A; Innocenti, I; Frustaci, A; Vitale, Candida; Petulla, M; de Fabritiis, P; Vignetti, M; Fazi, P; Foa, R.